Pliant Therapeutics (PLRX) Free Cash Flow (2019 - 2026)
Pliant Therapeutics (PLRX) reported Free Cash Flow of -$19.2 million for Q1 2026, up 60.86% year-over-year from -$12.0 million in Q1 2025, and down 9.72% quarter-over-quarter from -$17.5 million in Q4 2025.
Pliant Therapeutics (PLRX) Free Cash Flow (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Free Cash Flow data on file, last reported at -$19.2 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$19.2 million, up 60.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$98.6 million (up 44.23% YoY), and the FY2025 annual result was -$128.4 million, up 19.39% from the prior year.
- Free Cash Flow retreated to -$19.2 million in Q1 2026 per PLRX's latest filing, from -$17.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$17.5 million in Q4 2025 and troughed at -$49.1 million in Q1 2025.
- A 5-year average of -$30.5 million and a median of -$29.6 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow sank 90.24% in 2024, then jumped 63.39% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$29.6 million in 2022, then advanced by 15.12% to -$25.2 million in 2023, then sank by 90.24% to -$47.9 million in 2024, then soared by 63.39% to -$17.5 million in 2025, then decreased by 9.72% to -$19.2 million in 2026.
- Business Quant data shows PLRX's Free Cash Flow at -$19.2 million in Q1 2026, -$17.5 million in Q4 2025, and -$21.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 63,220.27 |
| 10 | Pliant Therapeutics | 74.16 Mn | 74.16 Mn | - | -19.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.23 Mn |
| Mar 31, 2026 | -19.23 Mn |
| Dec 31, 2025 | -17.53 Mn |
| Dec 31, 2025 | -17.53 Mn |
| Sep 30, 2025 | -21.34 Mn |
| Sep 30, 2025 | -21.34 Mn |
| Jun 30, 2025 | -40.45 Mn |
| Jun 30, 2025 | -40.45 Mn |
| Mar 31, 2025 | -49.13 Mn |
| Mar 31, 2025 | -49.13 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Sep 30, 2024 | -35.69 Mn |
| Sep 30, 2024 | -35.69 Mn |
| Jun 30, 2024 | -44.03 Mn |
| Jun 30, 2024 | -44.03 Mn |
| Mar 31, 2024 | -31.76 Mn |
| Mar 31, 2024 | -31.76 Mn |
| Dec 31, 2023 | -25.16 Mn |
| Dec 31, 2023 | -25.16 Mn |